These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1281 related items for PubMed ID: 25393645

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A.
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [Abstract] [Full Text] [Related]

  • 5. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.
    Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F.
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 9. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 10. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
    Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.
    J Bone Miner Metab; 2008 Aug; 26(6):624-34. PubMed ID: 18979163
    [Abstract] [Full Text] [Related]

  • 11. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA.
    J Clin Densitom; 2016 Aug; 19(3):346-51. PubMed ID: 26900146
    [Abstract] [Full Text] [Related]

  • 12. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
    Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C.
    Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
    Sheth NP, Smith JR, Winzenrieth R, Humbert L, Wang Y, Boxberger JI, Bostrom MP.
    J Bone Joint Surg Am; 2024 Jul 03; 106(13):1162-1170. PubMed ID: 38691582
    [Abstract] [Full Text] [Related]

  • 15. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 03; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 16. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F.
    Menopause; 2018 Jul 03; 25(7):767-771. PubMed ID: 29462094
    [Abstract] [Full Text] [Related]

  • 17. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 03; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 18. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 03; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 19. Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.
    Winzenrieth R, Humbert L, Boxberger JI, Weiss RJ, Wang Y, Kostenuik P.
    J Clin Densitom; 2022 Nov 03; 25(3):392-400. PubMed ID: 35033435
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T, Hijikata Y, Matsubara Y, Watanabe N.
    Cochrane Database Syst Rev; 2021 Jul 07; 7(7):CD013424. PubMed ID: 34231877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.